Ozempic vs Trulicity: Cost, Access, and Which GLP-1 Works Better for Women

What Is the Core Difference Between Ozempic and Trulicity?

Both drugs are once-weekly injectable GLP-1 receptor agonists approved for type 2 diabetes in adults. The core difference is potency. Semaglutide binds the GLP-1 receptor with higher affinity and has a longer effective half-life than dulaglutide, which translates to greater reductions in blood glucose and body weight at comparable doses. Trulicity has been on the market longer, carries a larger body of real-world use, and is currently easier to obtain.

How Each Drug Works in a Woman's Body

GLP-1 receptor agonists slow gastric emptying, reduce appetite signaling in the hypothalamus, and stimulate glucose-dependent insulin secretion. Women tend to have higher body-fat percentage and lower lean mass than men of equivalent BMI, which may affect how much weight they lose on either drug. The hypothalamic appetite circuits these drugs target also interact with estrogen. Estrogen loss during perimenopause and menopause down-regulates GLP-1 sensitivity in animal models, though direct human data in menopausal women on GLP-1 agonist response are limited (see Evidence Gaps below).

The SUSTAIN-7 Trial: The Only Direct Head-to-Head

The only randomized controlled trial comparing these two drugs is SUSTAIN-7, published in The Lancet Diabetes & Endocrinology in 2018. In 1,201 adults with type 2 diabetes, semaglutide 0.5 mg and 1 mg were compared head-to-head against dulaglutide 0.75 mg and 1.5 mg over 40 weeks. Semaglutide 1 mg produced weight loss of 5.5 to 7.3 kg vs 2.3 to 3.0 kg for dulaglutide, a difference that was statistically significant. A1C fell by approximately 1.5 percentage points on semaglutide 1 mg versus roughly 1.1 percentage points on dulaglutide 1.5 mg. About 40% of the SUSTAIN-7 participants were women, so sex-stratified efficacy data exist but were not the primary endpoint. The trial did not include a semaglutide 2 mg arm, which is now available.

Weight Loss: Which Drug Moves the Scale More?

Semaglutide produces meaningfully more weight loss. This matters especially for women whose weight gain is driven by hormonal shifts, insulin resistance in PCOS, or the redistribution of fat that accompanies perimenopause.

PCOS and Reproductive-Age Women

Polycystic ovary syndrome affects 8 to 13% of reproductive-age women and is tightly linked to insulin resistance. Neither Ozempic nor Trulicity is FDA-approved for PCOS, but both are used off-label to address metabolic dysfunction and to support ovulation in women with obesity-related anovulation. Small studies suggest GLP-1 agonists reduce androgen levels and improve menstrual regularity in women with PCOS, but no large randomized trial has directly compared semaglutide against dulaglutide for this indication. Given SUSTAIN-7's weight-loss advantage for semaglutide, clinicians at WomanRx generally reach for semaglutide first when weight reduction is the primary goal in a woman with PCOS who is not immediately trying to conceive.

Perimenopause and Postmenopausal Women

During perimenopause, estrogen fluctuations alter fat distribution from gynoid (hips, thighs) to visceral (abdomen), worsening insulin resistance even without significant weight gain. GLP-1 agonists reduce visceral fat preferentially. A secondary analysis of women in the SCALE obesity trials showed semaglutide's higher-dose form (2.4 mg, marketed as Wegovy) reduced visceral adiposity more than subcutaneous fat, though that dose is separate from Ozempic's 2 mg maximum. No published trial has compared dulaglutide against semaglutide specifically in perimenopausal or postmenopausal women with type 2 diabetes. Women in this life stage who are considering either drug should discuss how hormone therapy might interact with GLP-1 response with their clinician.

Does More Weight Loss Mean Better for Every Woman?

Not necessarily. Some women in perimenopause or with a history of disordered eating do better on a drug that produces more moderate appetite suppression. Dulaglutide's more gradual weight-loss trajectory may be preferable if rapid appetite suppression triggers restriction-rebound cycles or causes significant muscle loss without a concurrent protein and resistance-training plan.

Cardiovascular Outcomes: What the Trials Actually Show

Both drugs reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established or high-risk cardiovascular disease.

SUSTAIN-6 (Semaglutide)

The SUSTAIN-6 trial showed semaglutide (0.5 and 1 mg combined) reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 26% compared with placebo in high-risk adults with type 2 diabetes, over approximately 2 years.

REWIND (Dulaglutide)

The REWIND trial, published in The Lancet in 2019, enrolled 9,901 adults with type 2 diabetes, of whom 46% were women. This is a meaningful proportion compared with many cardiovascular trials. REWIND showed dulaglutide 1.5 mg reduced MACE by 12% relative risk reduction vs placebo (HR 0.88, 95% CI 0.79 to 0.99) over a median 5.4 years. REWIND included participants with a lower baseline cardiovascular risk profile than most other GLP-1 cardiovascular outcome trials, including patients with only cardiovascular risk factors rather than established disease. This makes REWIND's population more representative of many women in their 50s and 60s with type 2 diabetes who have not yet had a cardiac event.

What This Means if You Have Heart Disease Risk

If your cardiologist or primary care provider is choosing between these two drugs primarily for cardiovascular protection, either is a defensible choice. The trials are not directly comparable because they enrolled different populations, used different placebo controls, and ran for different durations. No trial has run a cardiovascular outcome comparison between semaglutide and dulaglutide head-to-head.

Cost and Access: The Practical Reality in 2025

Cost is where Trulicity has a real-world advantage for many women, though neither drug is cheap without insurance.

List Prices and Insurance Coverage

The approximate 2025 US list price for a one-month supply of Ozempic is around $935, while Trulicity runs approximately $800. Both manufacturers offer savings programs: the Novo Nordisk Ozempic savings card can reduce out-of-pocket cost to as low as $25/month for eligible commercially insured patients, and Eli Lilly's Trulicity savings program offers similar reductions. Patients on Medicare Part D are not eligible for manufacturer coupons, so out-of-pocket costs for that group depend entirely on their plan's formulary tier.

Formulary Tier and Prior Authorization

Trulicity has historically been placed on lower formulary tiers at more commercial insurance plans than Ozempic, partly because it launched earlier and has more negotiated contracts. In practice, your insurance plan's formulary determines which drug you pay less for, and the difference can be hundreds of dollars per month. Before choosing between the two, call your pharmacy benefit manager or use your plan's formulary lookup tool.

The Ozempic Shortage Problem

Ozempic has faced recurring supply shortages since 2022, driven by off-label use for weight loss. The FDA's drug shortage database has listed semaglutide injection intermittently. Trulicity has not experienced equivalent supply disruptions, making it a more reliable option if continuous medication access is a priority for you.

Compounded Semaglutide: A Note of Caution

During the shortage period, compounded semaglutide became widely marketed. The FDA has stated that compounded semaglutide raises serious safety concerns, including inconsistent dosing and use of non-approved salt forms (semaglutide sodium). Compounded dulaglutide is not widely available. If cost is your barrier and you are considering a compounding pharmacy, discuss the FDA's concerns with your provider first.

Side Effects: Where Women Experience the Differences

The GI side-effect profiles of both drugs are similar in kind but differ in intensity and frequency.

Nausea, Vomiting, and GI Tolerability

Nausea is the most common side effect of both drugs, affecting 15 to 20% of users during dose escalation. Semaglutide's stronger receptor binding produces more pronounced nausea, particularly in the first four to eight weeks of dose escalation. Women report nausea from GLP-1 agonists at higher rates than men in clinical trials, though whether this reflects true pharmacodynamic differences or reporting differences is not fully established. Women with a history of gastroparesis, eating disorders, or severe nausea in pregnancy should discuss this risk explicitly with their prescriber before starting either drug.

Injection Site and Device Differences

Both are subcutaneous injections. Ozempic uses a pen device with a 4 mm needle; Trulicity uses a single-use autoinjector with a concealed needle. Many women find the autoinjector format less anxiety-provoking. This is a practical consideration if injection anxiety is a barrier to adherence.

Pancreatitis and Thyroid Risk

Both drugs carry a black-box warning for thyroid C-cell tumors based on rodent data, and both are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN 2. The FDA label for both drugs includes this warning. Human relevance of the rodent thyroid findings is not established. Neither drug is known to cause pancreatitis at higher rates than seen in the background diabetic population, but both should be stopped if pancreatitis is suspected.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Both Ozempic and Trulicity are contraindicated in pregnancy. This section applies to every woman of reproductive age considering either drug.

Pregnancy Safety Data

Neither semaglutide nor dulaglutide has been studied in adequate controlled trials in pregnant women. Animal reproduction studies with semaglutide showed fetal harm at clinically relevant exposures. The FDA label for Ozempic states the drug should be discontinued at least 2 months before a planned pregnancy because of semaglutide's five-week half-life; two months allows for approximately four half-lives of clearance. Dulaglutide has a shorter half-life of approximately five days; the Trulicity label recommends stopping the drug before a planned pregnancy, with at least one to two months of washout as a reasonable clinical standard.

If you become pregnant while taking either drug, stop it immediately and contact your obstetric provider. Report the exposure to the relevant manufacturer's pregnancy registry.

Lactation

It is not known whether semaglutide or dulaglutide is excreted into human breast milk. Both are large peptide molecules that are unlikely to be absorbed intact from the infant gut, but formal human lactation studies have not been conducted. Given the absence of safety data, both drugs are generally not recommended during breastfeeding. Women who are postpartum and breastfeeding should discuss the timing of GLP-1 initiation with their provider.

Contraception Requirements

Because unintended pregnancy while on either drug carries meaningful fetal risk, women of reproductive age who are sexually active should use reliable contraception. GLP-1 agonists may reduce the absorption of oral contraceptives by delaying gastric emptying; this is a pharmacokinetic interaction worth discussing with your prescriber. An IUD, implant, or other non-oral method avoids this interaction entirely.

Evidence Gaps: What We Do Not Yet Know for Women

Women have been consistently under-represented in GLP-1 cardiovascular outcome trials. REWIND's 46% female enrollment is the best in this drug class, but even that trial was not powered to detect sex differences in MACE reduction. The following knowledge gaps are meaningful for clinical decision-making:

• Perimenopausal and postmenopausal women specifically. No published trial has compared semaglutide against dulaglutide in this life stage, and no trial has examined how concurrent menopausal hormone therapy affects GLP-1 efficacy or side-effect burden.
• PCOS. Head-to-head data in women with PCOS do not exist for this drug pair. Dose-response in the context of hyperandrogenism and insulin resistance is not characterized.
• Muscle mass preservation. Both drugs cause loss of lean mass alongside fat mass. Women already at higher risk of sarcopenia after menopause need specific data on GLP-1 effects on muscle in this population. This data does not exist for a direct semaglutide-versus-dulaglutide comparison.
• Bone density. Rapid weight loss from GLP-1 agonists may reduce bone mineral density. Women with osteopenia or osteoporosis should have their bone health monitored when starting either drug, but no trial has assessed this outcome in a women-specific analysis of either semaglutide or dulaglutide.

A structured framework for clinicians at WomanRx: when prescribing either drug to a woman over 45, assess bone density baseline, discuss muscle-preservation strategies (resistance training, protein targets of 1.2 to 1.6 g/kg/day), and revisit hormone therapy status as a co-variable in metabolic management.

Who This Is Right For (and Who Should Think Twice): By Life Stage

Reproductive-Age Women (18 to 40 years)

You are a reasonable candidate for either drug if you have type 2 diabetes or insulin-resistant PCOS with significant weight-related symptoms. Choose semaglutide if maximizing weight loss and A1C reduction is the priority. Choose dulaglutide if cost, shortage risk, or GI tolerability is the bigger concern. Stop either drug at least two months before trying to conceive.

Perimenopausal Women (40 to 55 years, irregular cycles)

Both drugs address visceral fat accumulation that worsens with estrogen decline. This is a clinically appropriate life stage to consider starting a GLP-1 agonist for type 2 diabetes with weight-related metabolic disease. Ask your provider whether menopausal hormone therapy and a GLP-1 together might address both the metabolic and vasomotor symptoms of perimenopause. Data directly supporting that combination are limited but emerging.

Postmenopausal Women (55 and older)

REWIND's population is particularly relevant here. If you have type 2 diabetes and cardiovascular risk factors but no established disease, dulaglutide's REWIND data apply to you more directly than to any other trial population in the GLP-1 class. Ozempic is still a reasonable choice; the weight-loss advantage over dulaglutide may be especially important if metabolic syndrome is the dominant concern.

Women Who Should Not Use Either Drug

You should not use Ozempic or Trulicity if you have a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, or are currently pregnant or breastfeeding. Women with type 1 diabetes should not use either drug as a standalone therapy.

Switching Between Ozempic and Trulicity: How It Works

You can switch from one drug to the other. No washout period is required because both drugs have overlapping mechanisms. The standard approach is to take the last dose of the first drug and then begin the second drug at its starting dose on the next scheduled injection day (one week later). Starting at the lowest dose of the new drug reduces GI side effects even if you were tolerating a higher dose of the prior drug, because receptor exposure patterns differ between the two molecules. Your provider should confirm the timing based on your specific dose history and reason for switching.

Ozempic vs Trulicity: Summary Comparison Table

| Feature | Ozempic (semaglutide) | Trulicity (dulaglutide) | |---|---|---| | Doses available | 0.5, 1, 2 mg weekly | 0.75, 1.5, 3, 4.5 mg weekly | | Weight loss (40 wks, SUSTAIN-7) | 5.5 to 7.3 kg (1 mg) | 2.3 to 3.0 kg (0.75 to 1.5 mg) | | A1C reduction (SUSTAIN-7) | ~1.5 pp (1 mg) | ~1.1 pp (1.5 mg) | | CV outcome trial | SUSTAIN-6: 26% MACE reduction | REWIND: 12% MACE reduction | | US list price (approx) | ~$935/month | ~$800/month | | Supply reliability (2025) | Intermittent shortage | Generally available | | Device | Pen, 4 mm needle | Autoinjector, concealed needle | | Pregnancy | Contraindicated; stop 2 months before TTC | Contraindicated; stop before TTC | | Approved for PCOS | No (off-label) | No (off-label) |